经肝动脉放疗性栓塞治疗肝癌的研究进展

doi:10.13481/j.1671-587x.20160341

[1] TorreLA,Bray F,Siegel RL.Global cancer statistics 2012[J].CA Cancer J Clin,2015,65(2):87-108.

[2] Villanueva A,Llovet JM.Liver cancer in 2013:Mutational landscape of HCC-the end of the beginning[J].Nat Rev Clin Oncol,2014,11 (2):73-74.

[3] Willatt J,Hannawa KK,Ruma JA.Image-guided therapies in the treatment of hepatocellular carcinoma:A multidisciplinary perspective[J].World J Hepatol,2015,7(2):235-244.

[4] Ni JY,Xu LF,Wang WD,et al.Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2014,20 (45):17206-17217.

[5] Hawkins MA,Dawson LA.Radiation therapy for heapatocellular carcinoma[J].Cancer,2006,106(8):1653-1663.

[6] Zeng ZC,Fan J,Tang ZY,et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J].Int J Radiat Oncol Biol Phys,2005,61(2):432-443.

[7] Lambert B,VandeWiele C.Treatment of hepatocellular carcinoma by means of radiopharmaceuticals [J].Eur J Nucl Med Mol Imaging,2005,32(8):980-989.

[8] Ariel IM,Pack GT.Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy[J].Cancer,1967,20(5):793-804.

[9] Blanchard RJ,Grotenhuis I,Lafave JW,et al.Treatment of experimental tumors; utilization of radioactive microspheres[J].Arch Surg,1964, 89:406-410.

[10] NeffR,Abdel-Misih R,Khatri J,et al.The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors[J].Cancer Invest, 2008,26(2):173-177.

[11] Yan ZP,Lin G,Zhao HY,et al.An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer[J].Cancer,1993,72(11):3210-3215.

[12] Sacco R,Mismas V,Marceglia S.Transarterial radioembolization for hepatocellular carcinoma:An update and perspectives[J].World J Gastroenterol,2015,21 (21):6518-6825.

[13] Riaz A,Awais R,Salem R.Side effects of yttrium-90 radioembolization[J].Front Onol,2014.doi:10.3389/fonc.2014.00198.

[14] Sangro B,Iarrairaegui L,Bilbao JI.Radioembolization for hepatocellular carcinoma[J].J Hepatol, 2012,56(2):464-473.

[15] Lewandowski RJ,Kulik LM,Riaz A,et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma:chemoembolization versus radioembolization[J].Am J Transplant,2009,9(8):1920-1928.

[16] She WH,Cheung TT,Yau TC,et al.Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection[J].Hepatobiliary Surg Nutr,2014,3 (4):185-193.

[17] Vouche M,Kulik L,Atassi R,et al.Radiological-pathological analysis of WHO,RECIST,EASL,mRECIST and DWI:Imaging analysis from a prospective randomized trial of Y90 ± sorafenib[J].Hepatology,2013,58 (5):1655-1666.

[18] Kulik L,Vouche M,Koppe S, et al.Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma[J].J Hepatol,2014,61 (2):309-317.

[19] Fujiki M,Aucejo F,Choi M,et al.Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation:where do we stand?[J]. World J Gastroenterol,2014,20 (18):5308-5319.

[20] Mazzaferro V,Sposito C,Bhoori S,et al.Yttrium-9 radioembolization for intermediate-advanced hepatocellular carcinoma:a phase 2 study[J].Hepatology,2013,57(5):1826-1837.

[21] Hilgard P,Hamami M,Fouly AE,et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma:European experience on safety and long-term survival[J].Hepatology,2010,52 (5):1741-1749.

[22] Salem R,Lewandowski RJ,Mulcahy MF,et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J].Gastroenterology,2010,138 (1):52-64.

[23] Liu D,Fong DY,Chan AC,et al.Hepatocellular carcinoma:surveillance CT schedule after hepatectomy based on risk stratification[J].Radiology,2015,274(1):133-140.

[24] Crissien AM,Frenette C.Current management of hepatocellular carcinoma[J].Gastroenterol Hepatol,2014,10(3):153-161.

[25] Bruix J,Gores GJ,Mazzaferro V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-855.

[26] Woo HY,Heo J.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis[J].Clin Molecul Hepatol,2015,21 (2 ):115-121.

[27] Lambert B,Sturm E,Mertens J,et al.Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma:4 years experience at the Ghent University Hospital[J].Eur J Nucl Med Mol Imaging,2011,38(12):2117-2124.

[28] Strigari L,Sciuto R,Rea S,et al.Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres:radiobiologic considerations[J].J Nucl Med,2010,51(9):1377-1385.

[29] Andreana L,Isgro G,Marelli L,et al.Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds:Trans-arterial radio-embolisation of HCC[J].Cancer Treat Rev,2012,38 (6):641-649.

[30] 王保信,武振明,张锐,等.联合应用雷替曲塞及表柔比星经肝功脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J].临床肝胆病杂志,2015,31(5):725-728.

[31] 祝普利,尹超,冯建龙.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968.

Progress research on transarterial radioembolization in treatment of hepatocellular carcinoma

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[2]	Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235.
[3]	Renyi YANG,Jincheng TANG,Kexiong LI,Wei PENG,Zhuo LIU,Ling WU,Puhua ZENG. Temporal trends and attributable risk analysis of liver cancer burden in China from 1990 to 2021 [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 199-210.
[4]	Limei WEN,Yali GUO,Wenmei MA,Taotao XUE,Ruoyu GENG,Chong MA,Xinhong ZHANG,Jianhua YANG. Bioinformatic analysis of TCGA database based on INPP4B gene expression in hepatocellular carcinoma and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1618-1629.
[5]	Huixian XU,Hui XU,Jishu QUAN,Feng ZHENG. Inhibitory effect of iridoid glycosides from Boschniakia rossica on hepatic preneolasia of rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 887-895.
[6]	Han LIN,Qiuyan YANG,Jieyue ZHONG,Bolun CHEN,Wangxia TONG. Improvement effect of cordycepin on ferroptosis in HepG2 cells induced by RSL3 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 576-589.
[7]	Xiaoyan WANG,Xuelian LI,Bin LIANG,Wenfei TIAN,Hailin MA,Zhijing MO. Analysis on relationship between CALU and prognosis of hepatocellular carcinoma patients and its mechanism based on transcriptome and single cell sequencing data [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 447-459.
[8]	Jing LOU,Lei ZHAO,Yanjie ZHU,Shuaiqiang YUAN,Fei WANG,Hangzhou ZHANG,Jiaojiao XU,Xiaoke YU,Liufa HOU. Effect of Fuzheng Ruanjian Anticancer Formula on malignant biological behaviors of hepatocellulars carcinoma HepG2 cells by regulating Akt/MDM2/P53 signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1654-1663.
[9]	Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015.
[10]	Huijuan SONG,Zhenhua XU,Dongning HE. Effect of apolipoprotein C1 expression on proliferation and apoptosis of human liver cancer HepG2 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 128-135.
[11]	Yanhong WEI,Chenxue YANG,Guangmin YANG,Shuai SONG,Ming LI,Haijiao YANG,Haifeng WEI. Inhibitory effect of downregulating HMGB2 expression on epithelial-mesenchymal transition of liver cancer LM3 cells and its AKT/mTOR signaling pathway mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 143-149.
[12]	Xiaoyan WANG,Hao ZHANG,Zehao GUO,Jun CAO,Zhijing MO. Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 168-177.
[13]	Xiaopeng YU,Renyi YANG,Zuomei HE,Puhua ZENG. Establishment and validation of nomogram of cancer specific survival of patients with hepatocellular carcinoma with negative alpha fetoprotein based on SEER Database [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 188-197.
[14]	Yong DONG,Lingyao XU,Jing HUA,Han LIANG,Dongya LIU,Junbo ZHAO,Zhenglu SUN,Cheng CHENG,Shutang WEI. Effect of macrophage exosomal lncRNA HULC on migration, invasion，and metastasis of hepatocellular carcinoma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1217-1226.
[15]	Wenjun DENG,Liantao HU,Binnan ZHAO,Xinyu DONG,Xuebin LI,Jie LI,Xinyan YANG,Xiaoli GUO,Yue LI,Yikun QU,Weiqun WANG. Effect of CXC chemokine ligand 10 on proliferation and migration of hepatocellular carcinoma SMMC-7721 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1227-1233.